The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback